J. E. Ross

发表

Educational antimicrobial susceptibility testing as a critical component of microbiology laboratory proficiency programs: American Proficiency Institute results for 2007-2011.

Ronald N. Jones, P. Rhomberg, H. Sader, 2013, Diagnostic microbiology and infectious disease.

Program 2011 United States: LEADER Surveillance Linezolid Surveillance Results for the

Ronald N. Jones, R. Mendes, R. Flamm, 2014 .

Summary of Linezolid Activity and Resistance Mechanisms Detected during the 2012 LEADER Surveillance Program for the United States

Ronald N. Jones, R. Mendes, R. Flamm, 2013, Antimicrobial Agents and Chemotherapy.

Linezolid Surveillance Results for the United States: LEADER Surveillance Program 2011

Ronald N. Jones, H. Sader, R. Mendes, 2012, Antimicrobial Agents and Chemotherapy.

Multicenter Investigation of Gepotidacin (GSK2140944) Agar Dilution Quality Control Determinations for Neisseria gonorrhoeae ATCC 49226

Ronald N. Jones, R. Flamm, Kelley A Fedler, 2016, Antimicrobial Agents and Chemotherapy.

ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries

Ronald N. Jones, D. Farrell, H. Sader, 2012, Journal of chemotherapy.

LEADER Program Results for 2009: an Activity and Spectrum Analysis of Linezolid Using 6,414 Clinical Isolates from 56 Medical Centers in the United States

Ronald N. Jones, D. Farrell, H. Sader, 2011, Antimicrobial Agents and Chemotherapy.

Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.

Ronald N. Jones, J. Turnidge, I. Kobayashi, 2009, Diagnostic microbiology and infectious disease.

ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries.

Ronald N. Jones, K. Yanagihara, S. Kohno, 2009, Diagnostic microbiology and infectious disease.

Comment on: Linezolid resistance in coagulase-negative staphylococci2

Ronald N. Jones, T. Fritsche, H. Sader, 2006 .

Daptomycin activity tested against linezolid-nonsusceptible gram-positive clinical isolates.

Ronald N. Jones, H. Sader, R. Mendes, 2009, Microbial drug resistance.

Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries.

Ronald N. Jones, T. Fritsche, H. Sader, 2007, Diagnostic microbiology and infectious disease.

Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.

Ronald N. Jones, T. Fritsche, H. Sader, 2006, The Journal of antimicrobial chemotherapy.

Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014)

Ronald N. Jones, R. Mendes, R. Flamm, 2016, Antimicrobial Agents and Chemotherapy.

Activity of Retapamulin (SB-275833), a Novel Pleuromutilin, against Selected Resistant Gram-Positive Cocci

Ronald N. Jones, Helio S. Sader, T. Fritsche, 2006, Antimicrobial Agents and Chemotherapy.

Activity of Dalbavancin Tested against Staphylococcus spp. and β-Hemolytic Streptococcus spp. Isolated from 52 Geographically Diverse Medical Centers in the United States

Ronald N. Jones, T. Fritsche, H. Sader, 2007, Journal of Clinical Microbiology.

Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.

Ronald N. Jones, T. Fritsche, H. Sader, 2005, International journal of antimicrobial agents.

Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program.

Ronald N. Jones, D. Farrell, R. Mendes, 2010, Diagnostic microbiology and infectious disease.

An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011.

Ronald N. Jones, H. Sader, R. Mendes, 2013, Diagnostic microbiology and infectious disease.

Determination of Disk Diffusion and MIC Quality Control Guidelines for JNJ-Q2, a Novel Quinolone

Ronald N. Jones, J. E. Ross, Lisa C. Liverman, 2011, Journal of Clinical Microbiology.

Eight-year (2002-2009) Summary of the Linezolid (Zyvox® Annual Appraisal of potency and Spectrum; ZAAPS) Program in European Countries

D. Farrell, R. Jones, R. Mendes, 2011, Journal of chemotherapy.

First Report of Staphylococcal Clinical Isolates in Mexico with Linezolid Resistance Caused by cfr: Evidence of In Vivo cfr Mobilization

Ronald N. Jones, R. Mendes, E. Rodriguez-Noriega, 2010, Journal of Clinical Microbiology.

Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.

Ronald N. Jones, T. Fritsche, H. Sader, 2007, International journal of antimicrobial agents.

Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.

Ronald N. Jones, T. Fritsche, H. Sader, 2005, Diagnostic microbiology and infectious disease.

In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program.

Ronald N. Jones, D. Farrell, R. Mendes, 2015, Diagnostic microbiology and infectious disease.

Disk Diffusion and MIC Quality Control Ranges for BC-3205 and BC-3781, Two Novel Pleuromutilin Antibiotics

Ronald N. Jones, S. Paukner, H. Sader, 2012, Journal of Clinical Microbiology.

LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).

Ronald N. Jones, T. Fritsche, H. Sader, 2007, Diagnostic microbiology and infectious disease.

Determination of Disk Diffusion and MIC Quality Control Guidelines for GSK2140944, a Novel Bacterial Type II Topoisomerase Inhibitor Antimicrobial Agent

Ronald N. Jones, R. Flamm, N. Scangarella-Oman, 2014, Journal of Clinical Microbiology.

Determination of Disk Diffusion and MIC Quality Control Guidelines for Solithromycin, a Novel Fluoroketolide Antibacterial, against Neisseria gonorrhoeae

Ronald N. Jones, S. Riedel, D. Farrell, 2015, Journal of Clinical Microbiology.

Several rRNA-Targeting Agents a Phenotype with Cross-Resistance to Streptococcus sanguinis Isolate Displaying

Ronald N. Jones, R. Mendes, L. Deshpande, 2014 .

Streptococcus sanguinis Isolate Displaying a Phenotype with Cross-Resistance to Several rRNA-Targeting Agents

Ronald N. Jones, R. Mendes, L. Deshpande, 2013, Journal of Clinical Microbiology.

LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers).

Ronald N. Jones, D. Farrell, H. Sader, 2012, Diagnostic microbiology and infectious disease.

Linezolid surveillance program results for 2008 (LEADER Program for 2008).

Ronald N. Jones, D. Farrell, R. Mendes, 2009, Diagnostic microbiology and infectious disease.

United States resistance surveillance results for linezolid (LEADER Program for 2007).

Ronald N. Jones, M. Castanheira, R. Mendes, 2008, Diagnostic microbiology and infectious disease.

Determination of disk diffusion and MIC quality control guidelines for GSK2251052: a novel boron-containing antibacterial.

Ronald N. Jones, N. Scangarella-Oman, J. E. Ross, 2013, Diagnostic microbiology and infectious disease.

Quality Control MIC Ranges Used for Telavancin with Application of a Revised CLSI Reference Broth Microdilution Method

Ronald N. Jones, R. Mendes, J. E. Ross, 2014, Journal of Clinical Microbiology.

Report of Linezolid Activity from the Linezolid Experience and Accurate Determination of Resistance (LEADER) Program for 2014: Monitoring Resistance Trends and Mechanisms

Ronald N. Jones, R. Mendes, R. Flamm, 2015 .

MIC quality control guidelines for doxycycline when testing gram-positive control strains by the reference methods.

Ronald N. Jones, J. E. Ross, 2004, Diagnostic microbiology and infectious disease.

Quality Control Guidelines for Susceptibility Testing of Retapamulin (SB-275833) by Reference and Standardized Methods

Ronald N. Jones, J. E. Ross, 2005, Journal of Clinical Microbiology.

In Vitro Activity of Fidaxomicin (OPT-80) Tested against Contemporary Clinical Isolates of Staphylococcus spp. and Enterococcus spp

Ronald N. Jones, S. Putnam, J. E. Ross, 2010, Antimicrobial Agents and Chemotherapy.

MIC Quality Control Guidelines and Disk Diffusion Test Optimization for CEM-101, a Novel Fluoroketolide

Ronald N. Jones, P. Rhomberg, J. E. Ross, 2009, Journal of Clinical Microbiology.

Determination of Disk Diffusion and MIC Quality Control Ranges for GSK1322322, a Novel Peptide Deformylase Inhibitor

Ronald N. Jones, Helio S. Sader, L. Miller, 2011, Journal of Clinical Microbiology.

Summary of Linezolid Activity and Resistance Mechanisms Detected during the 2012 LEADER Surveillance Program for the United States

Ronald N. Jones, R. Mendes, R. Flamm, 2013, Antimicrobial Agents and Chemotherapy.